The Latest
-
Shaun Lucas/PharmaVoice
The 2022 Red Jacket honorees
Our annual PharmaVoice 100 “hall of fame” winners raise the bar on transformative leadership in life sciences.
-
Illustration: Matthieu Bourel for Industry Dive
PharmaVoice 100The 2022 PharmaVoice 100
From standout executives to R&D pioneers — this year’s class of honorees is defining the next era of leadership.
-
Permission granted by Udit Batra
Profile // Red Jacket honorees 2022Red Jacket: Udit Batra
A combination of logic and love — that’s how the CEO of Waters Corp. leads and how he inspires those around him to “solve the problems that matter.”
-
Permission granted by Dr. Mark Goldberg
Profile // PharmaVoice 100Legacy Leaders: Dr. Mark Goldberg
The savvy clinical trials pro has built a global CRO by targeting the needs of the industry’s bustling biotech sector.
-
Permission granted by Dr. Jordan Schecter
Profile // PharmaVoice 100Innovators: Dr. Jordan Schecter
The VP of cellular therapy at Janssen has used collaboration, creative thinking and pragmatism to create a CAR-T multiple myeloma breakthrough.
-
Permission granted by Sastry Chilukuri
Profile // PharmaVoice 100Tech Wizards: Sastry Chilukuri
The co-CEO of Medidata is ushering in the next generation of clinical trial advancements, making research easier and more patient-focused than ever before.
-
Permission granted by Laxmi Bonagiri
Profile // PharmaVoice 100DE&I Champions: Laxmi Bonagiri
EClinical Solutions’ VP of India operations is creating a path to increase the number of women in senior leadership roles while changing the course of diseases for millions.
-
Permission granted by Scott Gray
Profile // PharmaVoice 100DE&I Champions: Scott Gray
The CEO, founder and president of Clincierge is championing diversity and inclusion within the company and beyond.
-
Permission granted by Peyton Howell
Profile // Red Jacket honorees 2022Red Jacket: Peyton Howell
The chief operating and growth officer of Parexel has sold her market access company and created award-winning DE&I programs, but it’s her role as “connector” that she takes the greatest pride in.
-
Permission granted by Quita Highsmith
ProfileRed Jacket: Quita Highsmith
The VP and chief diversity officer of Genentech is driving enterprise-wide strategies to influence how the biotech giant approaches DE&I — from clinical trials to career advancement.
-
Permission granted by Rosalind Brewer
Profile // PharmaVoice 100Disrupters: Rosalind Brewer
The CEO of Walgreens Boots Alliance is transforming the pharmacy powerhouse into a major new player in the healthcare space.
-
Permission granted by Jennifer Gottlieb
Profile // PharmaVoice 100DE&I Champions: Jennifer Gottlieb
The global president and chief client officer of Real Chemistry is dedicated to ensuring all voices at the agency are heard and everyone has a seat at the table.
-
Permission granted by Otis Johnson
Profile // PharmaVoice 100DE&I Champions: Otis Johnson
Clario’s chief diversity, inclusion and sustainability officer is looking to improve clinical trial recruitment with a bottom-up approach that first focuses on internal hiring practices.
-
Permission granted by Carl Turner
Profile // PharmaVoice 100Disrupters: Carl Turner
How Klick’s first-ever chief brand strategy officer is relying on collaboration to advance innovative strategies for clients and opportunities for people of color.
-
Permission granted by Johnna Wesley
Profile // PharmaVoice 100Innovators: Johnna Wesley
The vice president of Type 1 diabetes and kidney disease research at Novo Nordisk is leading the charge to deliver paradigm-changing breakthroughs in the space.
-
Permission granted by Fabio Gratton
Profile // Red Jacket honorees 2022Red Jacket: Fabio Gratton
The serial entrepreneur has relied on his gift for storytelling, creativity and a bit of “magic” as he’s launched one successful niche tech company after another.
-
Permission granted by David Katz
Profile // PharmaVoice 100Entrepreneurs: David Katz
As the founder and chief scientific officer of Sparrow Pharmaceuticals, David Katz is breathing new life into drugs that have previously been shelved.
-
Permission granted by Nello Mainolfi
Profile // PharmaVoice 100Entrepreneurs: Nello Mainolfi
Kymera Therapeutics’ CEO is chasing untreated disease targets by advancing a game-changing technology.
-
Permission granted by Kathy Lee-Sepsick
Profile // PharmaVoice 100Entrepreneurs: Kathy Lee-Sepsick
Kathy Lee-Sepsick, the founder of Femasys, is determined to change the game in long-neglected areas of women’s healthcare, some of which haven’t had much innovation in more than a century.
-
Permission granted by Samantha Du
Profile // PharmaVoice 100Entrepreneurs: Samantha Du
The CEO of Zai Lab is at the forefront of the movement to boost innovation in China’s biotech sector while delivering needed solutions to patients around the world.
-
Permission granted by Dawn Berry
Profile // PharmaVoice 100Entrepreneurs: Dawn Barry
The co-founder and president of LunaPBC is seeking to eliminate the middlemen in drug development by connecting patients — and their real-world data — directly with researchers.
-
Stock via Getty Images
Methadone at home? Emerging tech provides new tool in the fight against opioid addiction
Sonara Health’s inexpensive, specially engineered label and web app allow for at-home, digitally supervised dosing of high-cost or high-risks drugs.
-
Diego Camargo/PharmaVoice
Podcast
Woman of the Week: Agilent Technologies’ Dr. Katharine Knobil
As the first chief medical officer of the diagnostic testing company, Dr. Katharine Knobil is focused on moving the science forward beyond precision oncology to liquid biopsy.
-
Md Saiful Islam Khan via Getty Images
Feds could soon bring COVID-style fight to superbug threat
COVID-19 has inspired renewed urgency in the need for weapons to combat antimicrobial resistant infections and new hope of government funding to meet the challenge.
-
Petrovich9 via Getty Images
From the ‘go-go days’ to a bubble crunch — the biotech sector faces its next challenge
The highs of the sector in early 2021 gave way to a bear market that persisted into the second half of this year — but there's hope the bubble hasn't popped for good.
